Curis, Inc.

About Curis, Inc.

Curis, Inc. is a biotechnology company focused on developing innovative and differentiated therapeutics to improve the lives of cancer patients.

Products & Services

Emavusertib (CA-4948):A therapeutic targeting IRAK4 for hematologic malignancies such as AML/MDS and NHL/CLL/WM, under clinical activity stage in TakeAim Leukemia and TakeAim Lymphoma studies.

Fimepinostat:A drug targeting HDAC/PI3K for MYC-altered cancers, currently in clinical activity stage.

CA-170:A therapeutic targeting VISTA/PDL1 for PDL1/VISTA-expressing cancers, in clinical activity stage.

Erivedge:An approved drug targeting Hedgehog for Basal Cell Carcinoma, in commercial stage.

Emavusertib (CA-4948, IRAK4 inhibitor)

Fimepinostat (HDAC/PI3K)

CA-327 (TIM3/PDL1)

CA-170 (VISTA/PDL1)

Specialties

Cancer therapeutics Hematologic malignancies Immune checkpoint inhibitors IRAK4 inhibitors HDAC/PI3K inhibitors Oncology therapeutics Targeted cancer therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 80800000 MR: - FA: up to $80.8 million FAN: 80800000	D: 2026-01-09 FD: 2026-01-09	4 investors
2	RT: Private Placement T: - FT: Private Placement	A: 80800000 MR: - FA: up to $80.8 million FAN: 80800000	D: 2026-01-07 FD: 2026-01-07	2 investors
3	RT: Registered Direct and Concurrent Private Placement T: - FT: Registered Direct and Concurrent Private Placement	A: 7000000 MR: - FA: $7.0 million FAN: 7000000	D: 2025-07-02 FD: 2025-07-02	-
4	RT: Private Placement T: - FT: Private Placement	A: 12100000 MR: - FA: 12.1 million FAN: 12100000	D: 2024-10-29 FD: 2024-10-29	-
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15100000 MR: - FA: $15.1 million FAN: 15100000	D: 2023-07-06 FD: 2023-07-06	-

Private Placement Latest

2026-01-09

$80.8M

4 investors (Pro only)

Private Placement 2026-01-07

$80.8M

Registered Direct and Concurrent Private Placement 2025-07-02

$7.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rachel Blasbalg

Senior Director, Human Resources

J

James Dentzer

President & CEO

D

Diantha Duvall

Chief Financial Officer

A

Ahmed Hamdy

Chief Medical Officer

M

Maureen E. Lane

Vice President, Clinical and Translational Science

M

Mark Noel

Vice President, Technology Management & Intellectual Property

View 20 more team members with Pro

Unlock Full Team Directory

Recent News

Curis, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised